3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
7
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
3
Urologic Neoplasms
2
Neoplasm Metastasis
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Peripheral Nervous System Diseases
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Adenocarcinoma of the Bladder
1
Interventions
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
trastuzumab deruxtecan
2
Cisplatin
2
Biopsy
2
pembrolizumab
1
luprolide acetate gel depot
1
entrectinib
1
dehydroftorafur
1
darolutamide
1
ceralasertib
1
apalutamide
1
amivantamab
1
Surveys and Questionnaires
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Platinum
1
Pemetrexed
1
Leuprolide
1
Immunoglobulin G
1
Gonadotropin-Releasing Hormone
1
Glutamate Carboxypeptidase II
1
Fluorouracil
1
Docetaxel
1
Disulfides
1
Carboplatin
1
Bevacizumab
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
enfortumab vedotin
×
30 days
×
Clear all
No trials found.